Dimcho Bachvarov

List of Publications by Year
in descending order

67	2,689	159525	189801
papers	citations	30 h-index	50 g-index

67	67	67	4515
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model. International Journal of Molecular Sciences, 2020, 21, 4992.	1.8	2
2	Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. Journal of Translational Medicine, 2020, 18, 439.	1.8	15
3	LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/Î²-Catenin Pathway. International Journal of Molecular Sciences, 2020, 21, 1848.	1.8	6
4	Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer. PLoS ONE, 2019, 14, e0218621.	1.1	17
5	The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression. International Journal of Molecular Sciences, 2019, 20, 2264.	1.8	17
6	Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer. Pathology Research and Practice, 2019, 215, 152369.	1.0	2
7	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	1.1	67
8	Biocompatible Lipid Nanoparticles as Carriers To Improve Curcumin Efficacy in Ovarian Cancer Treatment. Journal of Agricultural and Food Chemistry, 2017, 65, 1342-1352.	2.4	55
9	Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells. Cell Cycle, 2017, 16, 693-706.	1.3	28
10	Systems biology combining human- and animal-data miRNA and mRNA data identifies new targets in ureteropelvic junction obstruction. BMC Systems Biology, 2017, 11, 31.	3.0	12
11	Altered expression of different GalNAc-transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. International Journal of Oncology, 2017, 51, 1887-1897.	1.4	24
12	Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFÎ²1-independent manner. Oncotarget, 2017, 8, 82506-82530.	0.8	20
13	A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. Journal of Proteomics, 2016, 145, 91-102.	1.2	21
14	Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. Data in Brief, 2016, 8, 342-349.	0.5	7
15	NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death and Disease, 2016, 7, e2269-e2269.	2.7	94
16	The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells. Oncotarget, 2016, 7, 14125-14142.	0.8	29
17	Histone deacetylase 1 and 2 regulate Wnt and p53 pathways in the ureteric bud epithelium. Development (Cambridge), 2015, 142, 1180-1192.	1.2	44
18	Role of aberrant glycosylation in ovarian cancer dissemination. Biomedical Reviews, 2015, 25, 83.	0.6	5

#	Article	IF	Citations
19	BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget, 2015, 6, 31522-31543.	0.8	84
20	Genome-wide analysis of gestational gene-environment interactions in the developing kidney. Physiological Genomics, 2014, 46, 655-670.	1.0	5
21	A 2-Stage, Single-Arm, Phase 2 Study of Epigallocatechin Gallateâ€"Enriched Green Tea Drink as a Maintenance Therapy in Women With Advanced-Stage Ovarian Cancer. Obstetrical and Gynecological Survey, 2014, 69, 207-208.	0.2	1
22	Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer, 2014, 14, 288.	1.1	33
23	A new paradigm for transcription factor TFIIB functionality. Scientific Reports, 2014, 4, 3664.	1.6	16
24	Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget, 2014, 5, 544-560.	0.8	89
25	Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Modern Pathology, 2013, 26, 1413-1424.	2.9	35
26	A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecologic Oncology, 2013, 131, 357-361.	0.6	43
27	Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecologic Oncology, 2013, 128, 356-363.	0.6	50
28	The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle, 2013, 12, 972-986.	1.3	83
29	Genome-wide analysis of the p53 gene regulatory network in the developing mouse kidney. Physiological Genomics, 2013, 45, 948-964.	1.0	16
30	Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells. PLoS ONE, 2013, 8, e65569.	1.1	34
31	Inhibition of RUNX2 Transcriptional Activity Blocks the Proliferation, Migration and Invasion of Epithelial Ovarian Carcinoma Cells. PLoS ONE, 2013, 8, e74384.	1.1	28
32	Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecologic Oncology, 2012, 127, 511-515.	0.6	45
33	Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle, 2012, 11, 2843-2855.	1.3	129
34	A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation. Gynecologic Oncology, 2012, 125, 720-726.	0.6	12
35	Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Molecular Oncology, 2011, 5, 438-453.	2.1	32
36	Histone Deacetylase (HDAC) Activity Is Critical for Embryonic Kidney Gene Expression, Growth, and Differentiation. Journal of Biological Chemistry, 2011, 286, 32775-32789.	1.6	86

#	Article	IF	Citations
37	COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. OMICS A Journal of Integrative Biology, 2011, 15, 383-392.	1.0	27
38	Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma. PLoS ONE, 2011, 6, e22469.	1.1	24
39	Strong cytotoxic effect of the bradykinin antagonist BKMâ€570 in ovarian cancer cells â€“ analysis of the molecular mechanisms of its antiproliferative action. FEBS Journal, 2010, 277, 5146-5160.	2.2	25
40	Novel combination of Celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle, 2010, 9, 1399-1410.	1.3	39
41	Molecular determinants of LPS-induced acute renal inflammation: Implication of the kinin B1 receptor. Biochemical and Biophysical Research Communications, 2009, 386, 407-412.	1.0	27
42	Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Modern Pathology, 2008, 21, 1002-1010.	2.9	51
43	Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics, 2008, 9, 99.	1.2	93
44	Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer, 2008, 8, 346.	1.1	11
45	The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. International Journal of Biochemistry and Cell Biology, 2008, 40, 2492-2507.	1.2	24
46	Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. Kidney International, 2007, 72, 442-454.	2.6	20
47	Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes. Biological Chemistry, 2006, 387, 15-22.	1.2	11
48	Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors. International Journal of Oncology, 2006, 29, 5.	1.4	39
49	Genes invoked in the ovarian transition to menopause. Nucleic Acids Research, 2006, 34, 3279-3287.	6.5	25
50	Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. International Journal of Oncology, 2006, 29, 5-24.	1.4	101
51	Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. International Journal of Oncology, 2006, 29, 919-33.	1.4	18
52	In vivo DNase I-mediated footprinting analysis along the human bradykinin B1 receptor (BDKRB1) gene promoter: evidence for cell-specific regulation. Biochemical Journal, 2005, 389, 37-46.	1.7	8
53	YY1 Is Regulated by O-LinkedN-Acetylglucosaminylation (O-GlcNAcylation). Journal of Biological Chemistry, 2003, 278, 14046-14052.	1.6	101
54	Agonist-Induced Translocation of the Kinin B1Receptor to Caveolae-Related Rafts. Molecular Pharmacology, 2002, 61, 546-553.	1.0	97

#	Article	IF	Citations
55	Bradykinin B2receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Canadian Journal of Physiology and Pharmacology, 2002, 80, 323-327.	0.7	33
56	Identification of two genes differentially expressed upon different spatial configuration of the MGH-U3 human bladder cancer cells. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 57-61.	0.8	0
57	In vivo protein-DNA interactions at the kinin B1 receptor gene promoter: No modification on interleukin-1 beta or lipopolysaccharide induction. Journal of Cellular Biochemistry, 2000, 78, 278-296.	1.2	26
58	Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. American Journal of Hypertension, 2000, 13, 1268-1273.	1.0	53
59	Kinin receptors. Clinical Reviews in Allergy and Immunology, 1998, 16, 385-401.	2.9	130
60	Altered frequency of a promoter polymorphic allele of the kinin B receptor gene in inflammatory bowel disease. Gastroenterology, 1998, 115, 1045-1048.	0.6	36
61	Structure and Genomic Organization of the Human B1Receptor Gene for Kinins (BDKRB1). Genomics, 1996, 33, 374-381.	1.3	56
62	Mapping of a Sequence Essential for the Nuclear Transport of theXenopusRibosomal Transcription Factor xUBF Using a Simple Coupled Translation-Transport and Acid Extraction Approach. DNA and Cell Biology, 1993, 12, 275-281.	0.9	7
63	Structure of human type II 5 alpha-reductase gene.. Endocrinology, 1992, 131, 1571-1573.	1.4	183
64	Heterogeneity in theXenopusribosomal transcription factor xUBF has a molecular basis distinct from that in mammals. FEBS Letters, 1991, 288, 55-59.	1.3	20
65	The RNA polymerase I transcription factor xUBF contains 5 tandemly repeated HMG homology boxes. Nucleic Acids Research, 1991, 19, 2331-2335.	6.5	103
66	Construction of aCColE1 plasmid bearing inducible high-copy-number phenotype. Folia Microbiologica, 1990, 35, 177-182.	1.1	5
67	Constitutive expression of a native human interferon-alpha 1 gene in Escherichia coli. International Journal of Biochemistry & Cell Biology, 1989, 21, 983-985.	0.8	10